During the initial 6 weeks, individuals may observe modest weight loss
The majority of effects seen upon DPP4-inhibitor treatment are ascribed to an increase in GLP-1 levels
Common Coverage Denials and Approval Barriers Blue Cross Blue Shield frequently denies semaglutide coverage based on body mass index (BMI) thresholds, requiring patients to demonstrate a BMI of 30 or higher, or 27 with weight-related comorbidities
Renal function should be checked if prolonged gastrointestinal symptoms occur, especially in those with existing kidney disease For injection site reactions: Rotate injection sites (abdomen, thigh, upper arm) to prevent localised irritation Allow the medication to reach room temperature before injecting Use proper injection technique as demonstrated by your healthcare provider Important safety considerations: Women using oral contraceptives should use non-oral or barrier methods for 4 weeks after starting tirzepatide and after each dose increase, as absorption may be affected [1] If you are taking insulin or sulphonylureas, your doctor may need to reduce these doses to prevent hypoglycaemia Report symptoms of gallbladder disease (severe right upper abdominal pain, jaundice) promptly Attend all scheduled follow-up appointments to monitor glycaemic control, weight, and overall tolerability Report any new, persistent, or worsening symptoms to your healthcare team promptly Do not discontinue Mounjaro without consulting your prescriber, as abrupt cessation may affect diabetes control Be aware of signs of pancreatitis (severe, persistent abdominal pain radiating to the back) and seek immediate medical attention if these occur Your healthcare provider can offer personalised advice based on your individual circumstances, comorbidities, and treatment goals
Allopurinol, the first-line ULT, suffers from reduced efficacy in patients with impaired conversion to its active metabolite, oxypurinol (OXY), and carries risks of severe hypersensitivity reactions (Mohamad et al., 2025
